Skip to main content

FDA approves treatment for people with mild forms of Alzheimer’s

Leqembi, which was developed by Eisai and Biogen, will cost about $26,000 a year
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.